Zoomcar Holdings reported a 2% rise in net revenue to $2.35 million for Q1 2026, with contribution margin expanding sharply to 70% from 49%, driven by a strategic shift to longer, higher-value trips. Contribution profit per booking increased 72% to $18.75, marking the eleventh consecutive quarter of positive contribution profit. Adjusted EBITDA loss narrowed 65% to $0.61 million, the lowest in nearly three years, reflecting improved operational efficiency and cost reductions, including lower losses from accidental damage and theft. The company also expanded its vehicle offerings with a two-wheeler pilot and is actively raising growth capital while pursuing debt restructuring and a potential uplisting to a major U.S. exchange.
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. The treatment showed a 41.7% overall response...
NEAR Protocol announced a Q3 Backers Summit scheduled for October 28. The event will focus on discussions about its House of Stake issuance proposal, updates on NEAR AI, and integration plans. Tokenomics and AI are key topics, with special guests exp...
